In this issue:
- Shingles risk with DMARDs for RA
- Tapering and stopping treatment for RA in stable remission
- Discontinuing biologic DMARDs for RA in remission
- Influence of obesity/overweight on disease activity in axial SpA
- COVID-19 risk in RA
- Low-dose glucocorticoids: withdraw or continue in systemic lupus erythematosus?
- Rheumatic/musculoskeletal disease flares and reactogenicity after COVID vaccination
- TNF inhibitor monotherapy vs. with conventional synthetic DMARDs in PsA
- Pain catastrophising hinders RA DAS28-ESR remission when CRP is normal
- Rituximab in polymyalgia rheumatica
Please login below to download this issue (PDF)